Daily Digest
Daily Digest
Pomegra Startups
Funding rounds, valuations, acquisitions, and IPOs - daily coverage of the companies shaping the private markets
Colombian payments startup Yuno raises $45M Series B led by Global PayTech Ventures to scale its AI-native payments orchestration platform toward $100B in annual transaction volume.
Dutch long-duration battery startup Ore Energy raises $43M backed by Plural to supply AI data centers with grid-stabilizing energy storage.
Berlin-based fintech Moss hits unicorn status after closing a €30M Series C led by Portage to expand its Finance AI platform for SMEs.
Immunology biotech Boulevard Bio exits stealth with $65M from Deerfield Management to advance a pipeline of multi-specific antibodies for autoimmune diseases including IgA nephropathy.
AI code review startup CodeRabbit raises $143M Series C at a $1.5B valuation, co-led by Atomico and Smash Capital, as revenue grows 5x year-over-year amid the AI-generated code surge.
UK air defense startup Cambridge Aerospace raises $300M Series C at a $3.4B valuation, backed by DFJ Growth and Accel, to scale its drone and missile interceptor products.
London-based AI cloud startup Volta exits stealth at a $2.4B valuation after raising $300M from a16z, NVIDIA, and Altimeter, and landing a reported €8.6B six-year compute deal with Anthropic.
Groq raises $350M at a $3.5B valuation as the AI infrastructure firm formally pivots from chip design to operating a GPU neocloud serving over 6 million developers.
AI video and image creation platform Higgsfield raises $400M Series B at a $5.4B valuation, backed by DST Global, after reaching $700M in annualized revenue and 30 million users.
AI inference chip startup Etched raises $700M at a $21B valuation led by Jane Street, which became its first customer by deploying Etched racks in its own datacenter.
Autonomy testing startup Agon emerges from stealth with $30M across pre-seed and seed rounds to build validation software for self-driving and autonomous systems.
Canadian biotech Biossil exits stealth with $70M to repurpose previously failed drug compounds for new therapeutic indications.
Pomegra